DK2069335T3 - Pyridin-3-ylderivater som immunomoduleringsmidler - Google Patents
Pyridin-3-ylderivater som immunomoduleringsmidlerInfo
- Publication number
- DK2069335T3 DK2069335T3 DK07826286.2T DK07826286T DK2069335T3 DK 2069335 T3 DK2069335 T3 DK 2069335T3 DK 07826286 T DK07826286 T DK 07826286T DK 2069335 T3 DK2069335 T3 DK 2069335T3
- Authority
- DK
- Denmark
- Prior art keywords
- yld
- pyridin
- derivatives
- immuno modulators
- immuno
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2006053187 | 2006-09-08 | ||
PCT/IB2007/053593 WO2008029370A1 (en) | 2006-09-08 | 2007-09-06 | Pyridin-3-yl derivatives as immunomodulating agents |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2069335T3 true DK2069335T3 (da) | 2013-02-18 |
Family
ID=38982768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07826286.2T DK2069335T3 (da) | 2006-09-08 | 2007-09-06 | Pyridin-3-ylderivater som immunomoduleringsmidler |
Country Status (27)
Country | Link |
---|---|
US (1) | US8288554B2 (da) |
EP (1) | EP2069335B1 (da) |
JP (1) | JP5253400B2 (da) |
KR (1) | KR101454937B1 (da) |
CN (1) | CN101522670B (da) |
AR (1) | AR062684A1 (da) |
AU (1) | AU2007292992B2 (da) |
BR (1) | BRPI0716633A2 (da) |
CA (1) | CA2661315C (da) |
CL (1) | CL2007002594A1 (da) |
CY (1) | CY1113858T1 (da) |
DK (1) | DK2069335T3 (da) |
ES (1) | ES2400163T3 (da) |
HK (1) | HK1135976A1 (da) |
HR (1) | HRP20130180T1 (da) |
IL (1) | IL197394A (da) |
MA (1) | MA30717B1 (da) |
MX (1) | MX2009002234A (da) |
MY (1) | MY150661A (da) |
NO (1) | NO20091409L (da) |
NZ (1) | NZ576059A (da) |
PL (1) | PL2069335T3 (da) |
PT (1) | PT2069335E (da) |
RU (1) | RU2454413C2 (da) |
SI (1) | SI2069335T1 (da) |
TW (1) | TWI399371B (da) |
WO (1) | WO2008029370A1 (da) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2069336E (pt) * | 2006-09-07 | 2013-03-07 | Actelion Pharmaceuticals Ltd | Derivados de piridin-4-ilo como agentes imunomoduladores |
MX2009002234A (es) | 2006-09-08 | 2009-03-16 | Actelion Pharmaceuticals Ltd | Derivados de piridin-3-il como agentes inmunomoduladores. |
CN101522645B (zh) | 2006-09-21 | 2013-01-09 | 埃科特莱茵药品有限公司 | 苯衍生物及其免疫调节剂的用途 |
BRPI0720043A2 (pt) * | 2006-12-15 | 2014-01-07 | Abbott Lab | Composto oxadiazol |
WO2008114157A1 (en) * | 2007-03-16 | 2008-09-25 | Actelion Pharmaceuticals Ltd | Amino- pyridine derivatives as s1p1 /edg1 receptor agonists |
PL2195311T3 (pl) * | 2007-08-17 | 2011-08-31 | Actelion Pharmaceuticals Ltd | Pochodne pirydynowe jako modulatory receptora S1P1/EDG1 |
KR20100092473A (ko) * | 2007-11-01 | 2010-08-20 | 액테리온 파마슈티칼 리미티드 | 신규한 피리미딘 유도체 |
JP2011513385A (ja) * | 2008-03-06 | 2011-04-28 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピリミジン−ピリジン誘導体 |
WO2009109906A1 (en) * | 2008-03-06 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Pyridine compounds |
EP2262782B1 (en) * | 2008-03-07 | 2012-07-04 | Actelion Pharmaceuticals Ltd. | Novel aminomethyl benzene derivatives |
BRPI0909055A2 (pt) * | 2008-03-07 | 2019-02-26 | Actelion Pharmaceuticals Ltd | composto derivado de piridin-2-il, composição farmacêutica que o contém e uso desse composto. |
CA2716448A1 (en) | 2008-03-17 | 2009-09-24 | Patrick Brossard | Dosing regimen for a selective s1p1 receptor agonist |
EP2177521A1 (en) * | 2008-10-14 | 2010-04-21 | Almirall, S.A. | New 2-Amidothiadiazole Derivatives |
DE102008063561A1 (de) | 2008-12-18 | 2010-08-19 | Bayer Cropscience Ag | Hydrazide, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Insektizide |
EP2403849B1 (en) * | 2009-03-03 | 2014-07-16 | Merck Serono S.A. | Oxazole pyridine derivatives useful as S1P1 receptor agonists |
DE102009002514A1 (de) * | 2009-04-21 | 2010-10-28 | Evonik Degussa Gmbh | Verfahren zur Herstellung von substituierten 1,4-Chinonmethiden |
JP2012526052A (ja) * | 2009-05-04 | 2012-10-25 | プロメティック・バイオサイエンシーズ・インコーポレイテッド | 置換芳香族化合物およびその薬学的使用 |
TW201107302A (en) * | 2009-06-26 | 2011-03-01 | Glaxo Group Ltd | Compounds |
GB0911130D0 (en) * | 2009-06-26 | 2009-08-12 | Glaxo Group Ltd | Novel compounds |
SI2454255T1 (sl) | 2009-07-16 | 2014-01-31 | Actelion Pharmaceuticals Ltd. | Derivati piridin-4-ila kot agonisti s1p1/edg1 |
US8399451B2 (en) * | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
ES2759949T3 (es) | 2009-10-29 | 2020-05-12 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos |
TW201120016A (en) * | 2009-12-08 | 2011-06-16 | Abbott Lab | Novel oxadiazole compounds |
US8835470B2 (en) | 2010-04-23 | 2014-09-16 | Bristol-Myers Squibb Company | Mandelamide heterocyclic compounds |
JP5788507B2 (ja) | 2010-07-20 | 2015-09-30 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 置換3−フェニル−1,2,4−オキサジアゾール化合物 |
US9187437B2 (en) | 2010-09-24 | 2015-11-17 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds |
JP2013544811A (ja) | 2010-11-03 | 2013-12-19 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および血管疾患の治療用のs1p1アゴニストとしての複素環式化合物 |
US9133179B2 (en) | 2011-01-19 | 2015-09-15 | Actelion Pharmaceuticals Ltd. | 2-methoxy-pyridin-4-yl-derivatives |
SI2885266T1 (sl) | 2012-08-17 | 2020-10-30 | Actelion Pharmaceuticals Ltd | Postopek za pripravo (2Z,5Z)-5-(3-kloro-4-((R)-2,3-dihidroksipropoksi) benziliden)-2-(propilimino)-3-(O-tolil)tiazolidin-4-on in v omenjenem postopku uporabljena vmesna spojina |
US9000016B2 (en) | 2012-11-05 | 2015-04-07 | Allergan, Inc. | 1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators |
UY35338A (es) | 2013-02-21 | 2014-08-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen |
UA115357C2 (uk) | 2013-03-15 | 2017-10-25 | Ідорсія Фармасьютікалз Лтд | Похідні піридин-4-ілу |
US9745295B2 (en) | 2013-04-26 | 2017-08-29 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
WO2015073140A1 (en) * | 2013-11-14 | 2015-05-21 | Allergan, Inc. | 1,3,4-alkenyl oxadiazole amino acid derivatives as sphingosine-1-phosphate receptors' modulators |
WO2015095445A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
US9783531B2 (en) | 2013-12-20 | 2017-10-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
US9670196B2 (en) | 2013-12-20 | 2017-06-06 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors |
WO2015108577A1 (en) * | 2014-01-15 | 2015-07-23 | Allergan, Inc. | Diphenyl urea derivatives as formyl peptide receptor modulators |
EP3116506B1 (en) | 2014-03-13 | 2019-04-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
UY36274A (es) | 2014-08-20 | 2016-02-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g |
CN114573574A (zh) | 2015-05-20 | 2022-06-03 | 爱杜西亚药品有限公司 | 一种化合物的结晶形式 |
US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
KR102482825B1 (ko) | 2016-09-02 | 2022-12-29 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 트리시클릭 헤테로시클릭 화합물 |
US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
AU2022221336A1 (en) * | 2021-02-10 | 2023-08-24 | Icahn School Of Medicine At Mount Sinai | OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL31990A (en) | 1968-04-26 | 1974-05-16 | Chinoin Gyogyszer Es Vegyeszet | Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same |
AU7686891A (en) | 1990-04-05 | 1991-10-30 | American National Red Cross, The | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
CA2051494C (en) | 1990-09-20 | 2006-03-14 | Robert J. Dinerstein | 1-aryl-3-pyridinyl-2-propene-1-ones as calcium uptake inhibitors |
DE4429465A1 (de) | 1994-08-19 | 1996-02-22 | Bayer Ag | Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde |
DE19540027A1 (de) * | 1995-10-27 | 1997-04-30 | Gruenenthal Gmbh | Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe |
US6423508B1 (en) | 1998-03-09 | 2002-07-23 | Smithkline Beecham Corporation | Polynucleotide sequences of human EDG-1c |
DE19904389A1 (de) * | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe |
MXPA02001764A (es) | 1999-08-19 | 2004-03-19 | Nps Pharma Inc | Compuestos heteropoliciclicos y su uso como antagonistas de receptor de glutamato metabotropico. |
CN1853630A (zh) | 2001-02-21 | 2006-11-01 | Nps制药公司 | 杂多环化合物及其在亲代谢的谷氨酸受体拮抗剂中的应用 |
WO2003062252A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Edg receptor agonists |
DE60330047D1 (en) | 2002-01-18 | 2009-12-24 | Merck & Co Inc | "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten" |
US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
EP1549640A4 (en) | 2002-06-17 | 2008-08-06 | Merck & Co Inc | 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS |
DE10237883A1 (de) | 2002-08-19 | 2004-03-04 | Merckle Gmbh Chem.-Pharm. Fabrik | Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie |
WO2004035538A1 (en) | 2002-10-15 | 2004-04-29 | Merck & Co., Inc. | Process for making azetidine-3-carboxylic acid |
US20050004186A1 (en) * | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
EP1625123A4 (en) | 2003-05-15 | 2007-08-29 | Merck & Co Inc | 3- (2-AMINO-1-AZACYCLYL) -5-ARYL-1,2,4-OXADIAZOLE AS S1P RECEPTOR AGONISTS |
TW200505416A (en) | 2003-08-12 | 2005-02-16 | Mitsubishi Pharma Corp | Bi-aryl compound having immunosuppressive activity |
CN1859908A (zh) | 2003-10-01 | 2006-11-08 | 默克公司 | 作为s1p受体激动剂的3,5-芳基、杂芳基或环烷基取代的-1,2,4-噁二唑类化合物 |
AU2004299456B2 (en) * | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
US8022063B2 (en) | 2004-05-29 | 2011-09-20 | 7Tm Pharma A/S | CRTH2 receptor ligands for medicinal uses |
WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
JP2008517915A (ja) | 2004-10-22 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | S1p受容体アゴニストとしての2−(アリール)アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環 |
CA2591399C (en) | 2004-12-13 | 2014-05-20 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medicinal use thereof |
WO2006100633A1 (en) | 2005-03-23 | 2006-09-28 | Actelion Pharmaceuticals Ltd | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS |
MX2007011669A (es) | 2005-03-23 | 2007-11-15 | Actelion Pharmaceuticals Ltd | Nuevos derivados de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1. |
KR101382733B1 (ko) | 2005-03-23 | 2014-04-14 | 액테리온 파마슈티칼 리미티드 | 면역조절물질로서의 수첨 벤조(c) 티오펜 유도체 |
CA2605594A1 (en) | 2005-04-22 | 2006-11-02 | Daiichi Sankyo Company, Limited | Heterocyclic compound |
AU2006239418A1 (en) | 2005-04-26 | 2006-11-02 | Neurosearch A/S | Novel oxadiazole derivatives and their medical use |
JP2008545767A (ja) | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 多環式オキサジアゾールまたはイソキサゾールおよびsip受容体リガンドとしてのそれらの使用 |
US20070043104A1 (en) | 2005-06-10 | 2007-02-22 | Luthman Ingrid K | UII-modulating compounds and their use |
KR20080024533A (ko) | 2005-06-24 | 2008-03-18 | 액테리온 파마슈티칼 리미티드 | 신규한 티오펜 유도체 |
CN101203220A (zh) | 2005-06-28 | 2008-06-18 | 阿斯利康(瑞典)有限公司 | 新用途 |
AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
ATE447568T1 (de) | 2006-01-24 | 2009-11-15 | Actelion Pharmaceuticals Ltd | Neue pyrinderivate |
GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
JP2009527501A (ja) | 2006-02-21 | 2009-07-30 | ユニバーシティ オブ バージニア パテント ファンデーション | S1p受容体アゴニストとしてのフェニル−シクロアルキル誘導体およびフェニル−複素環誘導体 |
AU2007251282A1 (en) | 2006-05-09 | 2007-11-22 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
AR061841A1 (es) | 2006-09-07 | 2008-09-24 | Actelion Pharmaceuticals Ltd | Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores. |
PT2069336E (pt) * | 2006-09-07 | 2013-03-07 | Actelion Pharmaceuticals Ltd | Derivados de piridin-4-ilo como agentes imunomoduladores |
MX2009002234A (es) | 2006-09-08 | 2009-03-16 | Actelion Pharmaceuticals Ltd | Derivados de piridin-3-il como agentes inmunomoduladores. |
CN101522645B (zh) | 2006-09-21 | 2013-01-09 | 埃科特莱茵药品有限公司 | 苯衍生物及其免疫调节剂的用途 |
MX2009003129A (es) | 2006-09-29 | 2009-04-06 | Novartis Ag | Derivados de oxadiazol con propiedades anti-inflamatorias e inmunosupresoras. |
UA91793C2 (ru) | 2006-10-07 | 2010-08-25 | Смс Зимаг Акциенгезелльшафт | Способ эксплуатации конвертера |
JP2008120794A (ja) | 2006-10-16 | 2008-05-29 | Daiichi Sankyo Co Ltd | ヘテロ環化合物を含有する医薬組成物 |
US20080138955A1 (en) * | 2006-12-12 | 2008-06-12 | Zhiyuan Ye | Formation of epitaxial layer containing silicon |
BRPI0720043A2 (pt) | 2006-12-15 | 2014-01-07 | Abbott Lab | Composto oxadiazol |
WO2008091967A1 (en) | 2007-01-26 | 2008-07-31 | Smithkline Beecham Corporation | Chemical compounds |
WO2008114157A1 (en) | 2007-03-16 | 2008-09-25 | Actelion Pharmaceuticals Ltd | Amino- pyridine derivatives as s1p1 /edg1 receptor agonists |
PL2195311T3 (pl) | 2007-08-17 | 2011-08-31 | Actelion Pharmaceuticals Ltd | Pochodne pirydynowe jako modulatory receptora S1P1/EDG1 |
KR20100092473A (ko) | 2007-11-01 | 2010-08-20 | 액테리온 파마슈티칼 리미티드 | 신규한 피리미딘 유도체 |
EP2222667B1 (en) | 2007-12-10 | 2013-02-20 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as agonists of s1p1/edg1 |
WO2009109906A1 (en) | 2008-03-06 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Pyridine compounds |
JP2011513385A (ja) | 2008-03-06 | 2011-04-28 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピリミジン−ピリジン誘導体 |
BRPI0909055A2 (pt) | 2008-03-07 | 2019-02-26 | Actelion Pharmaceuticals Ltd | composto derivado de piridin-2-il, composição farmacêutica que o contém e uso desse composto. |
EP2262782B1 (en) | 2008-03-07 | 2012-07-04 | Actelion Pharmaceuticals Ltd. | Novel aminomethyl benzene derivatives |
-
2007
- 2007-09-06 MX MX2009002234A patent/MX2009002234A/es active IP Right Grant
- 2007-09-06 MY MYPI20090939 patent/MY150661A/en unknown
- 2007-09-06 NZ NZ576059A patent/NZ576059A/en not_active IP Right Cessation
- 2007-09-06 CA CA2661315A patent/CA2661315C/en not_active Expired - Fee Related
- 2007-09-06 KR KR1020097006863A patent/KR101454937B1/ko not_active IP Right Cessation
- 2007-09-06 SI SI200731184T patent/SI2069335T1/sl unknown
- 2007-09-06 DK DK07826286.2T patent/DK2069335T3/da active
- 2007-09-06 ES ES07826286T patent/ES2400163T3/es active Active
- 2007-09-06 BR BRPI0716633-8A2A patent/BRPI0716633A2/pt not_active IP Right Cessation
- 2007-09-06 PL PL07826286T patent/PL2069335T3/pl unknown
- 2007-09-06 CN CN2007800333351A patent/CN101522670B/zh not_active Expired - Fee Related
- 2007-09-06 RU RU2009112726/04A patent/RU2454413C2/ru not_active IP Right Cessation
- 2007-09-06 AU AU2007292992A patent/AU2007292992B2/en not_active Ceased
- 2007-09-06 CL CL200702594A patent/CL2007002594A1/es unknown
- 2007-09-06 JP JP2009527263A patent/JP5253400B2/ja not_active Expired - Fee Related
- 2007-09-06 US US12/310,763 patent/US8288554B2/en not_active Expired - Fee Related
- 2007-09-06 PT PT78262862T patent/PT2069335E/pt unknown
- 2007-09-06 WO PCT/IB2007/053593 patent/WO2008029370A1/en active Application Filing
- 2007-09-06 EP EP07826286A patent/EP2069335B1/en active Active
- 2007-09-06 AR ARP070103941A patent/AR062684A1/es unknown
- 2007-09-07 TW TW096133600A patent/TWI399371B/zh not_active IP Right Cessation
-
2009
- 2009-03-04 IL IL197394A patent/IL197394A/en not_active IP Right Cessation
- 2009-03-18 MA MA31728A patent/MA30717B1/fr unknown
- 2009-04-07 NO NO20091409A patent/NO20091409L/no not_active Application Discontinuation
-
2010
- 2010-03-02 HK HK10102256.3A patent/HK1135976A1/xx not_active IP Right Cessation
-
2013
- 2013-03-04 HR HRP20130180TT patent/HRP20130180T1/hr unknown
- 2013-03-26 CY CY20131100255T patent/CY1113858T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2069335T3 (da) | Pyridin-3-ylderivater som immunomoduleringsmidler | |
DK2069336T3 (da) | Pyridin-4-yl-derivater som immunomodulerende midler | |
DK2144897T3 (da) | 8-Oxy-quinolinderivater som bradykinin B2-receptormodulatorer | |
ATE475662T1 (de) | Dihydropyrazolopyrimidinonderivate | |
ATE483711T1 (de) | Spiroindolinonderivate | |
ATE469905T1 (de) | Pyridopyrimidinonderivate | |
ATE512135T1 (de) | Spiroindolinonderivate | |
DK2035394T3 (da) | 2-pyrazincarboxamidderivater | |
DK2300465T3 (da) | Imidazopyridinderivater som hæmmere af receptortyrosinkinaser | |
DK2086939T3 (da) | Pyridiacarboxamid som II-beta-HSDI-inhibitorer | |
ES1065656Y (es) | Helicoptero | |
DK1928845T3 (da) | Aminodiazepiner som toll-lignende receptor-modulatorer | |
BRPI0714764A2 (pt) | Derivados substituídos de sulfonamida | |
DK2035549T3 (da) | Abcb5-positive mesenkymale stamceller som immunmodulatorer | |
DK2252609T3 (da) | Pyridin-2-yl-derivater som immunomodulerende midler | |
ATE544764T1 (de) | 5-hydroxymethyloxazolidin-2-onderivate | |
DK2007396T3 (da) | Enfumafungin-derivat som antimykotika | |
DK2049480T3 (da) | 2-arylindolderivater som mPGES-1-hæmmere | |
ATE492529T1 (de) | Sulfonamidderivate | |
DE602007001051D1 (de) | Projektor | |
DE112007001949A5 (de) | Partnerseitenleuchte | |
DE602007003121D1 (de) | Verpackung | |
FI7154U1 (fi) | Pakkaus | |
DK2041128T3 (da) | Substituerede gamma-lactamer som terapeutiske agenser | |
DE602008003432D1 (de) | Substituierte furoä2,3-büpyridinderivate als cannabinoid-1-rezeptormodulatoren |